HOXA-AS2 has demonstrated an oncogenic role in a variety of cancers, including pancreatic cancer 38, gastric cancer 39, breast cancer 40, bladder cancer 41, glioma 42, papillary thyroid cancer 43, 44, osteosarcoma 45, non-small lung cancer 46, gallbladder carcinoma 47, colorectal cancer 48, 49, and hepatocellular carcinoma 50, 51. Here, HOXA-AS2 is linked to urinary bladder carcinoma.